COL1A2 Gene Analysis for Ehlers-Danlos Syndrome Type VIIB | 2800 AED | DHA Licensed Dubai

Executive Summary & Core Metrics

Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM).
Clinical Guidance: Telephonic Post-Test Clinical Guidance by DHA‑licensed Medical Geneticist.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

This advanced genetic test screens for mutations in the COL1A2 gene associated with Ehlers-Danlos Syndrome Type VIIB (arthrochalasia type), characterized by severe joint hypermobility, skin hyperextensibility, and tissue fragility. The NGS technology offers unparalleled precision, enabling early diagnosis and personalized management for individuals with clinical suspicion or family history.

Test Overview & Methodology

Targeted Next-Generation Sequencing (NGS) of the COL1A2 gene at high depth (100% coding region coverage) ensures maximum diagnostic yield for Ehlers-Danlos syndrome type VIIB. This method outperforms broad exome approaches in cost, turnaround time, and sensitivity for this specific genetic condition.

Feature	Our UAE COL1A2 NGS Test	Standard Whole Exome Sequencing
Methodology	Targeted high‑depth NGS (100% coverage of COL1A2 coding regions)	Broad exome (>20,000 genes), lower depth per gene
Turnaround Time	3 – 4 Weeks	6 – 8 Weeks
Diagnostic Sensitivity for COL1A2	99.9%	≈95% (coverage gaps possible)
Pre‑test Genetic Counseling & Pedigree	Included	Often not included
Cost in UAE	2,800 AED	4,500 – 6,000 AED

Physician Insight & Safety Protocols

“Genetic testing for COL1A2 provides a vital clue in the clinical puzzle of Ehlers-Danlos syndrome. A positive result opens the door to targeted management and family screening, but it is only one piece of a comprehensive evaluation. I guide each patient through this discovery with empathy and clarity.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Medication Warning

Do not discontinue any prescribed medication without consulting your treating physician. Genetic test results must be interpreted alongside your full clinical picture.

Safety Exclusion Criteria & ER Red Flags

Exclusion: Active bleeding disorder or platelet count <50,000/µL — consult your doctor before blood draw.
Exclusion: Recent blood transfusion (<2 weeks) — may interfere with DNA extraction.
ER Red Flag: Sudden joint dislocation causing severe pain or neurovascular compromise.
ER Red Flag: Unexplained extensive bruising, arterial rupture, or organ prolapse — seek immediate emergency care.

Patient FAQ & Clinical Guidance

1. What is the accuracy of the COL1A2 NGS test for Ehlers-Danlos syndrome type VIIB?

Our test achieves a diagnostic sensitivity of 99.9% for pathogenic variants in the COL1A2 gene due to high‑depth sequencing and rigorous bioinformatics, making it the most reliable confirmation for EDS type VIIB in the UAE.

2. How is the sample collected, and is home collection available in Dubai and Abu Dhabi?

Our VIP mobile phlebotomy service dispatches a DHA‑licensed phlebotomist to your location between 8 AM and 11 PM across all Emirates, using a single blood draw or FTA card for minimal discomfort.

3. Will my insurance cover this genetic test, and how do I verify?

We provide direct billing verification via WhatsApp; send your insurance card image to +971 54 548 8731, and we will confirm coverage within one business hour.

UAE Regulatory & Data Privacy Adherence

DNA Labs UAE strictly adheres to the Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical testing and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Patient data is encrypted and handled with the highest confidentiality.

Clinical & Logistical Metadata

Test Name	COL1A2 Gene Analysis for Ehlers-Danlos Syndrome Type VIIB
Price (AED)	2,800
Turnaround Time	3 – 4 Weeks
Sample Type / Matrix	Peripheral Whole Blood (EDTA) or FTA Card
Methodology Used	Next-Generation Sequencing (NGS)
ICD-10-CM Code	Q79.6
LOINC Code	51966-4
DHA Facility License & Laboratory Address	License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE